Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China · Delayed Price · Currency is CNY

10.61

-0.12 (-1.12%)

Aug 14, 2026, 3:04 PM CST

-20.82% (1Y)

Market Cap	14.08B -21.9%
Revenue (ttm)	5.42B +2.1%
Net Income	380.47M -41.3%
EPS	0.26 -41.3%
Shares Out	1.47B
PE Ratio	40.92
Forward PE	18.29
Dividend	0.15 (1.37%)
Ex-Dividend Date	Jun 18, 2026

Volume	8,512,270
Open	10.96
Previous Close	10.73
Day's Range	10.47 - 10.96
52-Week Range	8.50 - 13.61
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,150

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002399

Full Company Profile

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial Statements